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Abstract: Adjuvant chemotherapy is a standard therapy for gastric cancer patients, however, treatment response 
is quite heterogeneous. Molecular biomarkers will be highly valuable to guide the therapy and predict the re-
sponse and prognosis in these patients. The antioxidant enzymes superoxide dismutase 2 (SOD2) and glutathione 
S-transferase pi 1 (GSTP1) are involved in oxidative stress and drug detoxification, which modulate the efficacy of 
anticancer drugs. Here, we investigated the clinical associations of two functional single nucleotide polymorphisms 
of SOD2 and GSTP1 in stage II-III postoperative gastric cancer patients. SOD2 rs4880 and GSTP1 rs1695 were 
genotyped in 207 patients received postoperative platinum and fluorouracil based chemotherapy and 304 patients 
who did not. SOD2 rs4880 CT/CC significantly associated with decreased median overall survival time of 23 months 
when compared to the TT genotype (mean overall survival time of 65.2 months, P=0.002) only for patients received 
adjuvant chemotherapy. Stratification analysis showed SOD2 rs4880 CT/CC affected most significantly the clinical 
outcome for patients with tumor arising at gastric body (HR, 5.707, P=0.002), well to moderately differentiated 
adenocarcinoma (HR, 4.900, P<0.001), tumor of intestinal type (HR, 4.398, P<0.001), or tumor size less or equal 
to 5 cm (HR, 2.490, P=0.004); while GSTP1 rs1695 GA/GG was significant decreased overall survival time among 
patients with tumor arising at fundus or cardia (HR, 3.001, P=0.004), or mucinous or signet-ring cell carcinoma (HR, 
4.750, P=0.042). The present study suggested the two polymorphisms would affect the adjuvant chemotherapy 
outcome in specific subtype of gastric cancer. SOD2 rs4880 could be used as a biomarker to predict the prognosis 
and response to therapy. 
Keywords: Adjuvant chemotherapy, gastric cancer, single nucleotide polymorphism, superoxide dismutase 2, glu-
tathione s-transferase PI 1, prognosis
Introduction
Although the death rate of cancer patients was 
gradually declining in the last decade, gastric 
cancer still represents a devastating disease in 
Asia [1, 2]. Surgery remains the mainstay treat-
ment, and the incorporation of perioperative 
chemoradiation or chemotherapy could im- 
prove patients’ surgical outcome. In general, 
comparing to surgery alone, the adjuvant che-
motherapy increased 5-year survival from 
49.6% to 55.3% in the meta-analysis [3]. To 
date, platinum and fluorouracil (PF) based adju-
vant chemotherapy has been widely accepted 
and shows significant improved local control 
rate and survival benefit for postoperative stage 
II-III gastric cancer [4]. However, there is still a 
proportion of stage II-III gastric cancer patients 
have early disease progression despite suffi-
cient period of adjuvant treatment in current pr- 
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Table 1. Characteristics of the two cohorts of the gastric cancer patients
Clinicopathologic features Chemotherapy  (n=207)
No chemotherapy  
(n=304) P 
Age (years, mean±SD) 59±9.48 60±10.74 0.404
Sex
    Male 166 130
    Female 41 74 0.237
Tumor sizea
    ≤5 cm 118 165
    >5 cm 89 139 0.587
Tumor locationb
    Antrum 42 59
    Fundus or cardia 78 104
    Body 51 103
    Multiple locations 7 21 0.116
Invaded depth of tumorc
    T1 0 4
    T2 18 29
    T3 1 6
    T4 188 261 0.163
Regional lymph nodec
    N0 47 67
    N1 55 71
    N2 55 103
    N3 50 59 0.268
Tumor stagec
    II 61 97
    III 146 207 0.558
Tumor differentiationb,d
    Well to moderately 61 84
    Poorly 130 196
    Mucinous 15 23 0.897
Lauren classificationb
    Intestinal type 64 85
    Diffuse type 142 219 0.449
SOD2 rs4880
    TT 151 223
    CT 47 68
    CC 3 8 0.673
GSTP1 rs1695
    AA 126 185
    GA 69 99
    GG 5 12 0.642
Abbreviations: A, adenine; C, cytosine; G, guanine; rs1695, A→G substitution at codon 105 
of the GSTP1 gene; rs4880, C→T transition at codon 16 of the SOD2 gene; T, thymine. 
aTumor size was measured by the length of the tumor. bPartial data were not available and 
statistics were based on available data. cData were defined according to the TNM classifica-
tion (AJCC 7th, seven edition of the American Joint Commission on Cancer Staging Manual) 
for gastric cancer. dClassification is based on the predominant pattern of tumor as tubular 
adenocarcinoma (well to moderately differentiated), poorly differentiated adenocarcinoma 
(poorly differentiated), mucinous carcinoma, and Signet-ring cell carcinoma is included as 
poorly differentiated. 
actice. Since there is no 
clear evidence that any 
conventional clinicopa- 
thological factors that 
could distinguish patie- 
nts who are likely to ben-
efit from adjuvant che-
motherapy or not [5], id- 
entifying biomarker that 
can help to individua- 
lize adjuvant therapy wo- 
uld allow tailored chem- 
otherapy regimens and 
avoid unnecessary tox-
icities and financial bur- 
dens.
One mechanism of anti-
cancer drugs is capable 
of increasing the intra-
cellular reactive oxygen 
species (ROS) levels to 
induce apoptosis [6]. Ex- 
cessive ROS induces oxi-
dative stress that trig-
gered hemostatic imbal-
ance, leading to DNA da- 
mage in cells or on con-
trary to malignant trans-
formation. Cancer cells 
survive under low hypox-
ic stress that ultimately 
contributes to malignant 
progression and chemo-
resistance whereas pro-
longed stress triggers 
cell death [7]. However, 
there have been argu-
ments that the oxidative 
stress produced during 
treatments with antineo-
plastic agents such as 
cisplatin and doxorubi-
cin could interfere with 
cell cycle, hence reduce 
the treatment efficacy of 
certain cell cycle-depen-
dent regimens [8]. Sup- 
eroxide dismutase 2 (SO- 
D2) and glutathione S- 
transferase pi 1 (GSTP1) 
are two antioxidant en- 
zymes, which are invo- 
lved in regulation of oxi-
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dative stress and drug detoxification. SOD2 is 
one of the major superoxide scavengers in 
mitochondria, converses endogenously pro-
duced superoxide into hydrogen peroxide by 
protecting cells from ROS- and lipid peroxida-
tion-related oxidative damage [9]. SOD2 
rs4880 (Val16Ala) is a C to T substitution in its 
mitochondrion targeting sequence, resulting in 
a substitution of valine (Val) by alanine (Ala). 
Compared with SOD2 Val variant, which is local-
ized in the mitochondrial membrane, the Ala 
variant presents in the mitochondrial ma- 
trix, shows increased enzymatic activity [10]. 
Up-regulation of SOD2 was observed in an oral 
squamous cell line that had been genetically 
engineered to be resistant to cisplatin [11], a 
widely used anticancer drug and an adjuvant 
chemotherapy regimen for gastric cancer. GS- 
TP1 is a member of a superfamily of dimeric 
phase II metabolic enzymes that play an impor-
tant role in the cell defense system [12]. 
Alkylating agents such as cisplatin and anthra-
cyclines are substrates of the GSTP1 isozyme 
[13]. GSTP1 rs1695 (Ile105Val) is an A to G 
transition at codon 105 that results in an iso-
leucine (Ile) to valine (Val) with decreased enzy-
matic activity and less effective detoxification. 
This genetic polymorphism is associated with 
drug resistance in a number of cancers [14, 
15], although it remains unclear whether these 
genetic variations could predict outcome of 
PF-based adjuvant chemotherapy in gastric 
cancer. 
In the current study, we investigated the clinical 
implications of the functional polymorphisms of 
SOD2 rs4880 and GSTP1 rs1695 in postopera-
tive Chinese gastric cancer patients received 
PF based adjuvant chemotherapy and com-
pared analyzed  their associations in another 
cohort of patients who did not receive any adju-
vant chemotherapy due to the financial rea-
sons. We also explored the prognostic associa-
tions of these SNPs in certain subtypes of gas-
tric cancer. 
Materials and methods
Ethics statement
The study protocol was approved by the In- 
stitutional Review Board of Nanjing Medical 
University (Nanjing, China). All patients have 
given written informed consents on the use of 
clinical specimens for medical research.
Study population
All patients had curative surgery and confirmed 
of stage II-III disease through pathological 
examinations and imaging studies at the Yixing 
People’s Hospital (Yixing, Jiangsu Province, 
China) between 1999 and 2006 were recruited 
for retrospective analysis [16]. None of them 
had perioperative chemoradiation or neoadju-
vant chemotherapy. Two hundred and seven 
patients had PF-based adjuvant chemotherapy 
within one month after surgery, and the other 
384 patients had not due to the financial rea-
sons. Overall survival was determined from the 
date of surgery to the date of death or last fol-
low-up (March 31, 2009, ranging from 3-118 
months). The demographic features and clini-
co-pathologic data are summarized in Table 1. 
Surgical specimens were processed immedi-
ately after the operation by fixing in buffered 
paraformaldehyde before embedding in paraf-
fin. The samples used for genotyping were re- 
viewed and classified by 2 independent pa- 
thologists. 
Treatment plan
The adjuvant chemotherapy consisted of at 
least 4 cycles of PF-based regimens, including 
combinations of cisplatin and fluorouracil, or 
oxaliplatin and fluorouracil. Chemotherapy was 
given only if the patient had neutrophil count of 
1.5×109/L, platelet count of 100×109/L, a 
hemoglobin level of ≥8 g/dl and no sign of 
organ toxicity. Antiemetics and mannitol diure-
sis were given according to institutional pro- 
tocols.
Genotyping 
Genomic DNA was extracted from tumor speci-
mens by proteinase K digestion, isopropanol 
extraction, and ethanol precipitation [17]. The 
SOD2 (rs4880) and GSTP1 (rs1695) SNPs were 
examined by multiplex SNaPshot technology 
using an ABI fluorescence-based assay allelic 
discrimination method (Applied Biosystems, 
Foster City, CA) as described previously [18]. 
The primers and extension primers for each 
SNP had previously been reported [16]. The 
SNPs were analyzed using an ABI 3130 Genetic 
Analyzer, and the genotypes were determined 
by using GeneMapper 4.0 software (Applied 
Biosystems). Genotyping was validated in ran-
domly selected 10% of samples by Sanger 
sequencing, and the results were 100% con- 
cordant.
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Statistical analysis
The SPSS Statistical Package for Windows (ver-
sion 16; SPSS Inc. Chicago, IL) was used for 
data analysis. All statistical tests were two-sid-
ed, and an association was considered statisti-
cally significant with a P value of <0.05. Kaplan-
Meier survival curves and the log-rank test 
were used for survival analysis. Chi-squared 
test was used to assess differences in the fre-
quency of characteristics between patient sub-
groups. Multivariate Cox regression analysis 
was used to determine the hazards ratios (HRs) 
and the independence of effects.
Results
Study population characteristics and survival
A total of 511 patients were recruited in this 
study. Two hundred and seven of them had 
PF-based adjuvant chemotherapy and 304 
patients did not have chemotherapy after cura-
tive surgery. There are no significant differenc-
es with respect to clinical and -pathological fac-
tors in the two cohorts. The clinical characteris-
tics and genotype information of the patients 
were summarized in Table 1. Eleven patients 
and fifteen patients were excluded for further 
SOD2 and GSTP1 analysis, respectively, beca- 
use of missing genotype information. The geno-
type frequency distribution for SOD2 rs4880 in 
all of the patients was 74.8% (374 patients) for 
the TT variant, 23% (115 patients) for the CT 
variant, 2.2% (11 patients) for the CC variant; 
for GSTP1 rs1695 was 62.7% (311 patients) for 
the AA variant, 33.9% (168 patients) for the GA 
variant, 3.4% (17 patients) for the GG variant. 
The genotype distributions of the two SNPs 
were found to be indifferent between both 
cohorts. 
In all patients, the median overall survival time 
(OS) was 62 months (95% CI, 46.4-77.6). Except 
for the patients with stage III was associated 
with a poorer median OS of 43 months than 
those with stage II (mean OS of 75 months, 
P<0.001). The mean OS of patients who had 
adjuvant chemotherapy was 61.5 months, 
which was longer but not significantly different 
from the median OS of patients had not adju-
vant chemotherapy (54 months, P=0.307). In 
the adjuvant chemotherapy cohort, 119 pa- 
tients received cisplatin and fluorouracil (CF) 
regimen and 88 of them received oxaliplatin 
and fluorouracil. The OS of oxaliplatin and fluo-
rouracil treated patients was not significant dif-
ferent from that of CF treated patients (P=0.12).
SOD2 rs4880 polymorphisms predicted overall 
survival in gastric cancer patients receiving PF-
based adjuvant chemotherapy
To determine the effects of the two polymor-
phisms of predicting clinical outcome, Cox 
regression analyses were used to assess asso-
ciations of SOD2 rs4880 and GSTP1 rs1695 
genotypes with overall survival in different 
Table 2. Associations of SOD2 rs4880 and GSTP1 rs1695 with gastric cancer-specific overall survival 
in both cohorts
Genetic Models Genotype Adjuvant chemotherapy (n=207) No chemotherapy (n=304)
MST (month) Pa HR (95% CI)a MST (month) Pa HR (95% CI)a
SOD2 rs4880
    Codominant model TT 65.2b 0.008 1 65.0 0.498 1
 CT 30.0 2.015 (1.267-3.204) 46.0 1.089 (0.753-1.575)
CC 14.0b 2.497 (0.599-10.406) 67.0b 0.292 (0.171-1.700)
    Dominant model TT 65.2b 0.002 1 65.0 0.949 1 
CT/CC 23.0 2.042 (1.298-3.212) 46.0 1.012 (0.707-1.448)
    Recessive model TT/CT 62.0b 0.310 1 66.7 0.276 1
CC 14.0 2.086 (0.505-8.620) 67.3b 0.529 (0.168-1.662)
GSTP1 rs1695
    Codominant model AA 62.7b 0.379 1 58.0 0.568 1
GA 43.0 1.325 (0.852-2.060) 48.0 1.163 (0.835-1.620)
GG 40.8b 0.597 (0.081-4.413) 62.0 0.840 (0.388-1.819)
    Dominant model AA 62.7b 0.340 1 58.0 0.506 1
GA/GG 52.1b 1.281 (0.827-1.984) 50.0 1.114 (0.810-1.533)
    Recessive model AA/GA 61.2b 0.542 1 50.0 0.565 1
GG 40.8b 0.538 (0.073-3.951) 62.0 0.799 (0.372-1.716)
Abbreviations: A, adenine; C, cytosine; CI, confidence interval; G, guanine; HR, hazard ratio; MST, median survival time; T, thymine. aCalculated in Cox regression and 
adjusted for age, sex and tumor stage. bMean survival time was presented when the median survival time could not be measured.
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genetic models for the two cohorts (Table 2). 
When adjusted by age, sex and tumor stage, 
neither of the two SNPs was associated with 
overall survival in the patients without adjuvant 
chemotherapy. However, for those had adju-
vant chemotherapy, there was a significant 
association between SOD2 rs4880 genotypes 
and overall survival time in the dominant model 
(P=0.002), where SOD2 rs4880 CT/CC variant 
genotypes increased the risk of death (HR, 
2.042, 95% CI: 1.298-3.212) when compared 
to the TT genotype (Table 2). The mean overall 
survival time of patients who carried a SOD2 
rs4880 TT genotype was 65.2 months, where-
as the median OS of patients who carried the 
CT/CC genotypes was only 23 months. Further 
analysis stratified by tumor stage revealed that 
SOD2 CT/CC genotypes significantly correlated 
with poor outcome independent of tumor stage. 
The mean survival times for patients who car-
ried a SOD2 rs4880 TT or CT/CC genotypes 
were 71.3 and 52 months in stage II (P=0.04), 
56 and 21 months in stage III (P=0.015), 
respectively (Figure 1). However, GTSP1 rs1695 
was not associated with overall survival regard-
less of adjuvant chemotherapy in different 
genetic models (Table 2). 
SOD2 and GSTP1 polymorphisms were associ-
ated with specific subtype of gastric cancer  
Recent investigations indicated that the dis-
tinct pathology of gastric cancer may represent 
different malignancies arising in the same 
organ, which could be due to the unique molec-
ular events involved in the different cell types 
and different initiating pathologic processes 
[19], and associated with different therapeutic 
response [20]. Hence, the associations be- 
tween SOD2 rs4880, GSTP1 rs1695 and sur-
vival of post-adjuvant chemotherapy patients 
were further explored by stratified analysis in 
tumors with different histology and anatomical 
sites and adjusted by age, sex and tumor stage 
(Table 3). Compared to the TT genotype, the 
SOD2 rs4880 CT/CC genotypes was signifi-
cantly associated with poor survival in gastric 
cancer patients with tumor arising at gastric 
body (HR, 5.707; 95% CI: 1.880-17.328, P= 
0.002), tumor size less or equal to 5 cm (HR, 
2.490; 95% CI: 1.346-4.603, P=0.004), well to 
moderately differentiated tumor (HR, 4.900; 
95% CI: 2.134-11.255, P<0.001) or tumor of 
intestinal type (HR, 4.398; 95% CI: 2.035-
9.502, P<0.001). Stratification analysis for 
GSTP1 rs1695 showed GA/GG genotype had a 
significant association with inferior survival 
with tumor arising at fundus or cardia (HR, 
3.001; 95% CI: 1.431-6.294, P=0.004) or 
mucinous or signet-ring cell tumor (HR, 4.750; 
95% CI: 1.056-21.363, P=0.042). 
Discussion
Adjuvant chemotherapy improved the overall 
survival for gastric cancer patients, however, 
Figure 1. Kaplan-Meier survival curves of SOD2 rs4880 for overall survival in gastric cancer patients received 
adjuvant chemotherapy. A. SOD2 rs4880 CT/CC associated with poor overall survival in stage II patients. B. SOD2 
rs4880 CT/CC associated with poor overall survival in stage III patients.
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there is no standard regimen established in the 
meta-analysis [5] and lack of biomarkers to 
guide the selections of regimens. In our study, 
we investigated the clinical significance of ge- 
netic polymorphisms of 2 ROS metabolic-relat-
ed genes, SOD2 and GSTP1, in Chinese gastric 
patients. SOD2 rs4880 CT/CC genotype was 
associated with poor overall survival only for 
the patients received PF-based adjuvant che-
motherapy; additionally, the clinical associa-
tions between studied polymorphisms and sur-
vival were influenced by certain pathological 
characteristics. 
Anti-neoplastic agents like platinum and fluoro-
uracil, the key components of adjuvant therapy, 
were shown to generate high level of ROS, as 
evidenced by increased lipid peroxidation pro-
duction and marked reduction of tissue gluta-
thione levels [21, 22]. SOD2 is an important 
regulator involved in the ROS metabolic pro-
cesses as an antioxidant defender, which may 
further interfere with the drug-resistance sig-
naling pathways. Significantly higher SOD2 lev-
els have been found in leukemia [23] and ovar-
ian cancer [24], suggesting increased SOD2 
activity was required for defense against ROS 
stress-induced injury and apoptosis [9]. In gas-
tric cancer, elevated levels of SOD2 activity, 
mRNA and protein have been found to be asso-
ciated with the aggressiveness of tumor and 
poor survival [25-29]. The Ala variant of SOD2 
rs4880 is more active than the Val variant, sug-
gesting that the homozygous CC genotype may 
present higher enzymatic activity than its TT 
counterpart [30]. Overexpression of SOD2 in- 
creases mitochondrion-derived H2O2 produc-
tion and leads to PTEN oxidation and activation 
of PI3K/Akt pathway activation [31], which is a 
major drug resistance related signaling path-
way. It has been shown that SOD2 antisense 
oligodeoxynucleotides could enhance the ef- 
fects of tumor necrosis factor-α and chemo-
therapy to eliminate highly resistant metastatic 
melanoma cells [32] and sensitize ovarian can-
cer cells to doxorubicin and paclitaxel [33]. 
These findings could be a possible explanation 
for the association of SOD2 rs4880 CT/CC with 
poor prognosis was only found in the patients 
received adjuvant chemotherapy but not in 
those who had not. In line with these findings, 
there were several studies verifying the associ-
ation of SOD2 rs4880 genotypes with thera-
peutic effect of cyclophosphamide-containing 
regimens in breast cancer [34, 35] and periop-
erative chemoradiation for rectal cancer [36]. 
Although adjuvant chemotherapy generally 
improved the overall survival for gastric cancer 
patients [3], our data showed that the carriers 
of the SOD2 rs4880 CT/CC genotypes had a 
significantly shortened overall survival time 
than those of SOD2 rs4880 TT genotype. St- 
ratified analysis on pathological characteristics 
showed SOD2 rs4880 CT/CC affected most 
significantly the clinical outcome for post-adju-
vant chemotherapy patients with tumor arising 
Table 3. Stratified analysis of two polymorphisms with gastric cancer overall survival in patients re-
ceived adjuvant chemotherapy (n=207)
Clinicopathologic Features SOD2  (deaths/patients)
GSTP1  
(deaths/patients)
TT CT/CC Pa HR (95% CI)a AA GA/GG Pa HR (95% CI)a
Tumor locationb
    Antrum 14/31 7/10 0.287 1.665 (0.651-4.261) 17/28 3/12 0.054 0.295 (0.085-1.022)
    Fundus or cardia 22/55 9/20 0.535 1.284 (0.583-2.830) 12/42 20/34 0.004 3.001 (1.431-6.294)
    Body 11/42 5/7 0.002 5.707 (1.880-17.328) 9/30 7/18 0.599 1.318 (0.471-3.686)
Tumor size
    ≤5 cm 29/86 17/29 0.004 2.490 (1.346-4.603) 27/69 20/46 0.765 1.094 (0.607-1.970)
    >5 cm 26/65 12/21 0.097 1.803 (0.898-3.621) 22/57 15/28 0.214 1.532 (0.782-3.003)
Tumor differentiationb
    Well to moderately 18/47 11/13 <0.001 4.900 (2.134-11.255) 19/40 11/21 0.574 0.879 (0.464-2.390)
    Poorly 32/95 13/31 0.220 1.501 (0.784-2.875) 26/78 18/46 0.583 1.185 (0.646-2.172)
    Mucinous or signet-ring cell 5/9 5/6 0.081 4.256 (0.835-21.693) 4/8 6/7 0.042 4.750 (1.056-21.363)
Lauren classificationb
    Intestinal type 19/51 11/12 <0.001 4.398 (2.035-9.502) 20/41 11/23 0.818 1.096 (0.502-2.394)
    Diffuse type 36/100 18/38 0.086 1.654 (0.932-2.937) 29/85 24/51 0.166 1.470 (0.852-2.536)
Abbreviations: A, adenine; C, cytosine; CI, confidence interval; G, guanine; HR, hazard ratio; T, thymine. aCalculated in multivariate Cox regression and adjusted by age, 
sex and tumor stage. bPartial data were not available and statistics were based on available data.
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at gastric body, tumor size less or equal to 5 
cm, well to poorly differentiated adenocarcino-
ma, or tumor of intestinal type. These findings 
suggested that PF based adjuvant chemothera-
py might not be given to the patients who had 
SOD2 rs4880 CT/CC genotypes. Future studies 
are needed before implementation of personal-
ized treatment strategy for this population. 
GSTP1 participates in the intracellular ROS 
metabolism by catalyzing the reaction of gluta-
thione to conjugate with exogenous and endog-
enous electrophiles, which yields more water-
soluble and less reactive glutathione S-conju- 
gates [37]. Polymorphisms of GSTP1 rs1695 
has been demonstrated with different enzy-
matic activity [38], and its Val allele is much 
more protective against cisplatin and carbopla-
tin than the Ile allele in in vitro experiment [39]. 
Studies in gastric cancer, GSTP1 rs1695 was 
found to be correlated with the occurrence of 
adverse drug effect in oxaliplatin-based che-
motherapy [40] but not associated with res- 
ponse to cisplatin and 5-fluorouracil chemo-
therapy in a neoadjuvant setting [41], On the 
other hand, it was also reported that the GSTP1 
rs1695 homozygote and heterozygote G allele 
can provide protective effect for patients re- 
ceived platinum or 5-fluorouracil containing 
chemotherapy with colorectal cancer [42], non-
small cell lung cancer [43] and ovarian cancer 
[44]; while several other studies on esophageal 
cancer [45] and breast cancer [46] these geno-
types are associated with worse chemothera-
peutic outcome. Proximal gastric cancer, as 
tumor at fundus and cardia/gastroesophageal 
junction, is recognized as a different type of 
gastric cancer. It has been reported that proxi-
mal gastric cancer had distinctive risk factors 
than distal gastric cancer, [47], unfavorable 
clinical response [20] and prognosis [48].  
Our studies showed that GSTP1 rs1695 GA/GG 
genotypes were not associated with overall sur-
vival regardless of patients’ postoperative tre- 
atment when compared to AA genotype, ins- 
tead, GSTP1 rs1695 GA/GG genotypes strongly 
affected patients with cancer arising at gastric 
fundus or cardia, or mucinous or signet-ring cell 
carcinoma. To our knowledge, there is the first 
reported such association between specific 
markers and cancer type. Further investiga-
tions on the roles of ROS-related genes in drug 
response for selected gastric cancer subtype 
are needed.  
In conclusion, genotyping for SOD2 rs4880 
could distinguish postoperative stage II or III 
gastric cancer patients who might or might not 
benefit from PF-based adjuvant chemotherapy. 
Moreover, SOD2 rs4880 and GSTP1 rs1695 
showed specific influences on postoperative 
chemotherapy outcome in specific subtype of 
gastric cancer. These findings suggested that 
clinical usage of these SNPs indicator in gastric 
cancer could be possible, but should be care-
ful, and taken other factors such as pathologi-
cal characters, chemo regimens and treatment 
strategies into consideration. Our findings pro-
vide a solid foundation for future prospective 
clinical trials to validate these findings and 
design for effective regimens for personalized 
therapy.
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